A detailed history of Coston, Mc Isaac & Partners transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Coston, Mc Isaac & Partners holds 14 shares of VRTX stock, worth $5,714. This represents 0.0% of its overall portfolio holdings.

Number of Shares
14
Previous 14 -0.0%
Holding current value
$5,714
Previous $6,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 01, 2023

SELL
$314.42 - $351.91 $2,200 - $2,463
-7 Reduced 33.33%
14 $4,000
Q1 2023

Apr 19, 2023

BUY
$283.23 - $323.1 $1,982 - $2,261
7 Added 50.0%
21 $6,000
Q2 2022

Sep 21, 2022

BUY
$234.96 - $292.55 $3,289 - $4,095
14 New
14 $4,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $105B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Coston, Mc Isaac & Partners Portfolio

Follow Coston, Mc Isaac & Partners and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Coston, Mc Isaac & Partners, based on Form 13F filings with the SEC.

News

Stay updated on Coston, Mc Isaac & Partners with notifications on news.